Shots:
The company has filed a P-I/II IND with the FDA to begin clinical trials of CYPS317 for mod. to sev. Psoriasis
In animal studies, a single dose of CYPS317 matched or exceeded multiple anti-IL-23 mAb doses, showing durable effects and reduced disease recurrence
CYPS317 is an investigational allogeneic fibroblast spheroid therapy for mod. to…
Chronic diseases like diabetes, heart disease, and hypertension are among the leading causes of death worldwide. These conditions affect millions of people, placing a significant strain on individuals, families, and healthcare systems. While pharmaceutical advancements have revolutionized treatment options, they cannot address every aspect of a patient’s journey.
To tackle the complex challenges of chronic disease…

